New cocktail therapy targets tough liver cancer with blood clot

NCT ID NCT07327788

Recruiting now Disease control Sponsor: Nanfang Hospital, Southern Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of an experimental immunotherapy (QL1706), a blood vessel blocker (bevacizumab), and chemotherapy given directly into the liver artery for people with advanced liver cancer that has caused a clot in the main portal vein. The goal is to see if this approach can shrink tumors and extend life. About 38 participants will receive the treatment every three weeks for up to two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Iparomlimab and tuvonralimab (QL1706) plus bevacizumab and chemotherapy (raltitrexed and oxaliplatin)
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced liver cancer that has spread into the main portal vein, potentially slowing tumor growth and improving survival.
What could go wrong: This is an early Phase II trial with only 38 participants, so results may not apply to everyone. The combination of multiple drugs increases the risk of serious side effects, and the cancer may still progress despite treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BEVACIZUMAB are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma portal vein thrombosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BEVACIZUMAB HEPATECELLULAR CARCINOMA IPAROMLIMAB AND TUVONRALIMAB INJECTION QL1706 RALOX-HAIC（HEPATIC ARTERIAL INFUSION CHEMOTHERAPY WITH RALTITREXED AND OXALIPLATIN TYPE VP3/4 PORTAL VEIN TUMOR THROMBOSIS

Contacts and locations

Locations

Nanfang Hospital of Southern Medical University
RECRUITING

Guangzhou, Guangdong, 510515, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.